Eugene Zhukovsky Joins GO Therapeutics as Chief Technology Officer
Dr. Zhukovsky is an accomplished leader in the development of immune-therapeutics, such as T-cell bispecifics and immune checkpoint inhibitors.
GO Therapeutics Enters into a License Agreement with Roche for New Glycotargeting Bispecific Cancer Treatment
Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.
GO Therapeutics Appoints Dr. Robert J. Wills to Board of Directors
Dr. Wills is an accomplished, seasoned senior executive whose 37-year career spans directing R&D, business development and alliance management for major pharmaceutical firms.
Salubris Pharmaceuticals Invests $5 Million in GO Therapeutics
Strategic investment to help accelerate antibody development programs against novel solid tumor targets.
This is next-generation immuno-oncology.
© 2020 GO Therapeutics. All rights reserved.
Privacy Policy | Contact Us | Web Design: Someone Creative